2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

Hindricks, Gerhard; Potpara, Tatjana; Dagres, Nikolaos; Arbelo, Elena; Bax, Jeroen J.; Blomström‐Lundqvist, Carina; Boriani, Giuseppe; Castellà, Manuel; Dan, G A; Dilaveris, Polychronis; Fauchier, Laurent; Filippatos, G.; Kalman, J.; Meir, Mark La; Lane, Deirdre A.; Lebeau, Jean‐Pierre; Lettino, Maddalena; Lip, G Y H; Pinto, Fausto J.; Thomas, G. Neil; Valgimigli, Marco; Gelder, I. C. Van; Putte, Bart P. van; Watkins, Caroline L

doi:10.15829/1560-4071-2021-4701

Cited by 210 publications

(510 citation statements)

References 0 publications

Supporting

Mentioning

463

Contrasting

Unclassified

Order By: Relevance

“…Atrial fibrillation is one of the most common sustained arrhythmias encountered in clinical practice and is associated with a decreased quality of life and increased mortality 1 . The pathogenesis of AF is multifactorial and complex, with multiple risk factors and etiologies coexisting.…”

Section: Methodsmentioning

confidence: 99%

“…The concept of upstream therapy is included in both the American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology (ESC) AF guidelines 1,16 . Both angiotensin receptor blockers (ARBs) and angiotensin‐converting enzyme inhibitors (ACEIs) have been associated with a reduction in new‐onset AF in patients with hypertension left ventricular dysfunction and left ventricular hypertrophy 17 .…”

Section: Methodsmentioning

confidence: 99%

“…However, a meta‐analysis published in 2011 including 134,755 participants found the benefit of statins to reduce AF in short‐term trials is not sustained in longer‐term clinical trials 21 . Upstream use of statin therapy solely to prevent AF is not currently endorsed by the most recent 2020 ESC AF guidelines 1 …”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

The role of inflammation in the pathogenesis and treatment of arrhythmias

et al. 2022

View full text Add to dashboard Cite

The pathogenesis of arrhythmias is complex and multifactorial. The role of inflammation in the pathogenesis of both atrial and ventricular arrhythmias (VA) has been explored. However, developing successful pharmacotherapy regimens based on those pathways has proven more of a challenge. This narrative review provides an overview of five common arrhythmias impacted by inflammation, including atrial fibrillation (AF), myocardial infarction, arrhythmogenic cardiomyopathy, cardiac sarcoidosis, and QT prolongation, and the potential role for anti‐inflammatory therapy in their management. We identified arrhythmias and arrhythmogenic disease states with the most evidence linking pathogenesis to inflammation and conducted comprehensive searches of United States National Library of Medicine MEDLINE® and PubMed databases. Although a variety of agents have been studied for the management of AF, primarily in an effort to reduce postoperative AF following cardiac surgery, no standard anti‐inflammatory agents are used in clinical practice at this time. Although inflammation following myocardial infarction may contribute to the development of VA, there is no clear benefit with the use of anti‐inflammatory agents at this time. Similarly, although inflammation is clearly linked to the development of arrhythmias in arrhythmogenic cardiomyopathy, data demonstrating a benefit with anti‐inflammatory agents are limited. Cardiac sarcoidosis, an infiltrative disease eliciting an immune response, is primarily treated by immunosuppressive therapy and steroids, despite a lack of primary literature to support such regimens. In this case, anti‐inflammatory agents are frequently used in clinical practice. The pathophysiology of arrhythmias is complex, and inflammation likely plays a role in both onset and duration, however, for most arrhythmias the role of pharmacotherapy targeting inflammation remains unclear.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The role of inflammation in the pathogenesis and treatment of arrhythmias

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Paroxysmal AF was diagnosed according to the guidelines established by the European Society of Cardiology (Hindricks et al, 2021).…”

Section: Study Populationmentioning

confidence: 99%

Association between adiponectin‐to‐leptin ratio and heart rate variability in new‐onset paroxysmal atrial fibrillation: A retrospective cohort study

Zhu

Chen

Wang

et al. 2021

Noninvasive Electrocardiol

View full text Add to dashboard Cite

Background:The adiponectin-to-leptin (A/L) ratio has been identified as a potential surrogate biomarker for metabolic disorders. However, it remains unknown whether the serum A/L ratio is associated with heart rate variability in paroxysmal atrial fibrillation (AF).Methods: For this retrospective study, we included consecutive patients who underwent 24-h long-range electrocardiogram examination in our center for paroxysmal AF. The results of echocardiography, heart rate variability tests, and blood tests were also retrieved. Multivariate line regression analysis was performed to evaluate identify factors independently associated with heart rate variability.Results: Among the 85 included patients with paroxysmal AF, the median A/L ratio was 1.71. Univariate analysis indicated that patients with a low A/L ratio (<1.71, n = 42) had a lower high-frequency (HF) power and a higher hs-CRP level, lowfrequency (LF) power, and LF/HF ratio than those with a high A/L ratio (≥1.71, n = 43).Multivariate linear regression analysis showed that the serum leptin concentration was independently and positively associated with LF (β = 0.175, p = .028), while the serum adiponectin concentration was independently and positively associated with HF (β = 0.321, p = .001). Moreover, the A/L ratio was independently and negatively associated with the LF/HF ratio (β = −0.276, p = .007).

show abstract

“…Cancer patients have a risk of atrial fibrillation (AF) 47% higher than patients without cancer [ 1 , 2 , 3 ]. Conversely, an increased risk of incidentally finding cancer in patients with known AF has also been reported so that this relationship might be bidirectional [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Breast Cancer and Atrial Fibrillation

Mauro

Lucà²,

Tetta

et al. 2022

JCM

View full text Add to dashboard Cite

This study aims to establish the incidence of atrial fibrillation (AF) in breast cancer (BC) patients, focusing on staging and anti-cancer treatment. A meta-analysis was conducted to investigate the incidence of AF in BC patients and compare this incidence to other cancers. Furthermore, we evaluated the occurrence of AF as an adverse effect of biological therapies vs. non-biological therapies vs. biological therapies + non-biological therapies in BC. Finally, we compared the incidence of AF in early BC and metastatic BC. Thirty studies were included. Twenty-two studies focused on BC, encompassing 166,271 patients. In the BC group, 2.7% of patients developed AF, while in the “all cancer” group, 5.8% of patients developed AF. In addition, there was no difference between different types of therapies (p = 0.61) and between early and metastatic BC (p = 0.57). The type of anti-cancer therapy and the staging of BC does not influence AF’s occurrence in this neoplastic disease.

show abstract

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

Abstract: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

Cited by 210 publications

References 0 publications

The role of inflammation in the pathogenesis and treatment of arrhythmias

The role of inflammation in the pathogenesis and treatment of arrhythmias

Association between adiponectin‐to‐leptin ratio and heart rate variability in new‐onset paroxysmal atrial fibrillation: A retrospective cohort study

Breast Cancer and Atrial Fibrillation

Contact Info

Product

Resources

About